Trial · NCT04145258
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of all-cause death | Up to 40 weeks | |
| Secondary | Rate of all-cause death | Up to 8 weeks | |
| Secondary | Rate of all-cause death or loss to follow-up | Up to 40 weeks | |
| Secondary | Rate of new central neurological event or aggravation of a central neurological event existing at baseline | Up to 40 weeks | |
| Secondary | Rate of grade 3-4 adverse events (DAIDS adverse events grading table) | Up to 40 weeks | |
| Secondary | Rate of serious adverse events | Up to 40 weeks | |
| Secondary | Rate of solicited treatment related adverse events | Up to 40 weeks | |
| Secondary | Percentage of patients with disability | 40 weeks | |
| Secondary | M. tuberculosis culture conversion rate | 1 week and 4 weeks | |
| Secondary | Time to culture positivity | Up to 40 weeks | |
| Secondary | Time to first hospital discharge | Up to 40 weeks | |
| Secondary | Cost-effectiveness incremental ratio of trial interventions | Up to 40 weeks | |
| Secondary | Prevalence of resistance to anti-TB drugs among patients with positive culture at inclusion | Up to 40 weeks | |
| Secondary | Subset of patients: In vitro bactericidal activity of anti-TBM treatment | 1 week and 4 weeks | |
| Secondary | Subset of patients: Maximum Plasma Concentration [Cmax] of rifampicin and linezolid | 1 week and 4 weeks | Plasma Cmax, cerebrospinal fluid \[CSF\] Cmax, and plasma/CSF Cmax ratio |
| Secondary | Subset of patients: Minimum Plasma Concentration [Cmin] of rifampicin and linezolid | 1 week and 4 weeks | Plasma Cmin, cerebrospinal fluid \[CSF\] Cmin, and plasma/CSF Cmin ratio |
| Secondary | Subset of patients: Area Under the Curve [AUC] of rifampicin and linezolid | 1 week and 4 weeks | Plasma AUC, cerebrospinal fluid \[CSF\] AUC, and plasma/CSF AUC ratio |
| Secondary | Subset of patients: Time for maximal concentration [Tmax] of rifampicin and linezolid | 1 week and 4 weeks | Plasma Tmax, cerebrospinal fluid \[CSF\] Tmax, and plasma/CSF Tmax ratio |
| Secondary | Subset of patients: Half-life (t1/2) of rifampicin and linezolid | 1 week and 4 weeks | Plasma t1/2, cerebrospinal fluid \[CSF\] t1/2, and plasma/CSF t1/2 ratio |
| Secondary | HIV-infected participants: Rate of new AIDS-defining illnesses | Up to 40 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04145258/registered